Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0434 -0.0056 (-11.43%)

Streaming Delayed Price Updated: 10:13 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pharmather Hldgs Ltd

< Previous 1 2 Next >

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance ↗

September 27, 2023

The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.

Via Benzinga

NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years ↗

September 12, 2023

NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.

Via Benzinga

Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗

September 11, 2023

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification

Via Benzinga

Topics Artificial Intelligence

PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application ↗

September 06, 2023

Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t

Via Benzinga

Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗

July 24, 2023

Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal...

Via Benzinga

PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage ↗

July 18, 2023

PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives ↗

June 28, 2023

Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.

Via Benzinga

Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets ↗

June 27, 2023

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic...

Via Benzinga

PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement ↗

June 20, 2023

Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary...

Via Benzinga

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗

May 08, 2023

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

Via Benzinga

Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track ↗

May 03, 2023

Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and D

Via Benzinga

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗

April 05, 2023

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...

Via Benzinga

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update ↗

April 03, 2023

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...

Via Benzinga

Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval ↗

March 30, 2023

PharmaTher Holdings Ltd.

Via Benzinga

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗

February 27, 2023

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...

Via Benzinga

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind ↗

February 22, 2023

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through...

Via Benzinga

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

Via Benzinga

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation ↗

February 07, 2023

Specialty ketamine company PharmaTher Holdings Ltd.

Via Benzinga

Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics ↗

February 06, 2023

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically...

Via Benzinga

MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗

February 06, 2023

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve

Via Benzinga

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗

February 03, 2023

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

Via Benzinga

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News ↗

January 21, 2023

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...

Via Benzinga

Psychedelics Market Could Reach $12B By 2029, Says New Report ↗

January 19, 2023

A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before...

Via Benzinga

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products ↗

January 11, 2023

Two psychedelics companies have shared their updates and key milestones to be reached this 2023.

Via Benzinga

FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status ↗

December 15, 2022

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

Via Benzinga

Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder ↗

November 01, 2022

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Daily Courier: Single Column

Daily Courier

Pharmather Hldgs Ltd (OP:PHRRF)

Headline News about Pharmather Hldgs Ltd

Contact us

Sections

Services

Search